BiotechTube

TP-03 (Lotilaner Ophthalmic Solution), 0.25%

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy

Conditions

Healthy

Trial Timeline

Feb 9, 2021 → Sep 3, 2021

NCT ID
NCT05138861

About TP-03 (Lotilaner Ophthalmic Solution), 0.25%

TP-03 (Lotilaner Ophthalmic Solution), 0.25% is a phase 1 stage product being developed by Tarsus Pharmaceuticals for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT05138861. Target conditions include Healthy.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05138861Phase 1Completed

Competing Products

20 competing products in Healthy

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
33
ValsartanNovartisPhase 1
33
CSL112 + PlaceboCSLPhase 1
32
UT-15CUnited TherapeuticsPhase 1
30
VNA-318 + PlaceboBiotrialPhase 1
25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
25
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
25
Radiolabeled TRV130TrevenaPhase 1
25
TRV130A + Dextrose in WaterTrevenaPhase 1
25
TRV734TrevenaPhase 1
25
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
33
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
33
KPL-404Kiniksa PharmaceuticalsPhase 1
28
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
33
Propranolol + PseudoephedrineEli LillyPre-clinical
23
LY2157299Eli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 1
33
LY3015014 + PlaceboEli LillyPhase 1
33
LOXO-783Eli LillyPhase 1
33
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
33

Other Products from Tarsus Pharmaceuticals

Lotilaner ophthalmic solution, 0.25% + Vehicle controlApproved
80
TP-03 + TP-03 VehiclePhase 3
72
TP-03, 0.25% + TP-03 VehiclePhase 2/3
60
Vehicle of TP-03Phase 2
47
Lotilaner Gel, 2.0%Phase 2
47